HIV-1 Clinical Trial
— BONBOOfficial title:
Prospective Evaluation of Body Composition, Bone Health and Hormonal Status After Initiation of an Integrase-inhibitor-based Anti-retroviral Therapy in Treatment-naïve HIV-1-infected Individuals
NCT number | NCT03708289 |
Other study ID # | UZB BONBO |
Secondary ID | |
Status | Terminated |
Phase | |
First received | |
Last updated | |
Start date | September 2016 |
Est. completion date | October 2018 |
Verified date | September 2016 |
Source | Universitair Ziekenhuis Brussel |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Improved survival of people living with HIV has resulted in an increased occurrence of other
comorbidities, such as cardiovascular, renal, bone and endocrine pathologies.
The data that is currently available on cART-associated changes in bone mineral density, body
composition and hormonal values is short-term and mainly derived from patients initiating
cART in accordance with previous treatment guidelines. As current guidelines recommend
earlier cART initiation and as PI-based regimens are becoming less frequently used, a
favorable outcome on bone health, body composition measures and endocrine status might be
expected.
This study will therefore prospectively document alterations in bone mineral density, body
composition and endocrine status in HIV-infected patients in whom, in the current treatment
era, an INSTI-based cART regimen is initiated as a first line regimen.
Status | Terminated |
Enrollment | 120 |
Est. completion date | October 2018 |
Est. primary completion date | October 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Documented and confirmed HIV-1-infection - Aged 18 years or above - Naïve to anti-retroviral treatment, unless anti-retrovirals were taken in the context of occupational or non-occupational post-exposure prophylaxis or in the context of prevention of mother-to-child transmission - Willingness to sign the written informed consent Exclusion Criteria: - Pregnancy and breastfeeding - Patients receiving medical care through an 'emergency care package' |
Country | Name | City | State |
---|---|---|---|
Belgium | UZ Brussel | Jette |
Lead Sponsor | Collaborator |
---|---|
Universitair Ziekenhuis Brussel |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of changes in BMD from baseline | 144 weeks of follow-up | ||
Primary | Assessment of changes in trunk fat from baseline | 144 weeks of follow-up | ||
Primary | Determination of the incidence of subclinical and clinical hypothyroidism | Within 144 weeks of follow-up | ||
Secondary | Correlation between T-scores obtained by Achilles bone ultrasonometer (screening tool) and hip and spine DXA scan (gold standard) | 144 weeks of follow-up | ||
Secondary | Correlations between changes in body composition and endocrine values | 144 weeks of follow-up | ||
Secondary | Correlation between changes in VAT and trunk fat and changes in waist circumference | 144 weeks of follow-up | ||
Secondary | Description of changes in body composition in relation to the resting energy expenditure | 144 weeks of follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01968551 -
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
|
Phase 3 | |
Completed |
NCT02547844 -
Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla
|
Phase 4 | |
Terminated |
NCT01345630 -
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1
|
Phase 3 | |
Terminated |
NCT01173276 -
Intrauterine Insemination In HIV-Discordant Couples
|
N/A | |
Completed |
NCT00807443 -
Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1
|
Phase 2 | |
Completed |
NCT01140139 -
Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed by Repeated Treatment Interruptions
|
Phase 1 | |
Withdrawn |
NCT00340223 -
HLA-B35 Alleles and AIDS
|
N/A | |
Completed |
NCT00097006 -
Retrovirus Epidemiology Donor Study-II (REDS-II)
|
N/A | |
Completed |
NCT02217904 -
A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)
|
Phase 1 | |
Completed |
NCT00772902 -
ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial
|
Phase 4 | |
Completed |
NCT04006704 -
Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets
|
Phase 1 | |
Terminated |
NCT03060629 -
A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa
|
Phase 2 | |
Recruiting |
NCT00981695 -
Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers
|
Phase 1/Phase 2 | |
Completed |
NCT01084343 -
Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects
|
Phase 1 | |
Completed |
NCT00982579 -
Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected Mothers
|
Phase 1 | |
Completed |
NCT00665847 -
TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents
|
Phase 2 | |
Completed |
NCT00098293 -
Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine
|
Phase 3 | |
Completed |
NCT05944848 -
A Study of CL-197 Capsules in Healthy Participants
|
Phase 1 | |
Completed |
NCT00479999 -
Phase 1 Safety Study of Two Experimental HIV Vaccines
|
Phase 1 | |
Completed |
NCT01192035 -
PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial
|
Phase 4 |